Gels, Patches & Microneedles – Is Transdermal Drug Delivery Finally Coming of Age?

Greystone Associates Analyzes Transdermal Technologies, Therapies and Trends

Amherst, NH (PRWEB) March 14, 2006 –- Since the mid-90’s transdermal drug delivery has been the ‘next best thing’ in drug delivery. During that time, the market share of transdermal prescription products has grown steadily but far from the lofty expectations and analyst projections that were proclaimed for it. So what is the potential for transdermal delivery? And when will this potential be realized?

“Our research indicates that transdermal delivery may finally be positioned to make some waves,” explains George Perros, Greystone Managing Director. “It won’t be overnight – nothing ever is in this highly regulated industry – but a convergence of market and technology factors affecting the pharmaceutical industry at large will, to a large degree, favor transdermal drug products.”

Advances in the areas of excipients, drug solubility and transdermal dosing are beginning to attract new players and investors. Growth in this sector will also be driven by the pressure to extend market protection for numerous drugs with soon-to-expire patents, and Rx-to-OTC switching.

“We’re beginning to see some fairly exotic therapeutic targets for transdermal patches and gels,” adds Perros. “Transdermal drug candidates for such diverse conditions as depression, osteoporosis and CNS disorders are currently winding their way through the clinical trial process.”

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology assessment.

Contact:

Mark Smith

Voice: 603-595-4340

Fax: 603-804-0466

Greystone Associates (http://www.greystoneassociates.org)

Source: Greystone Associates

###